WO2014010658A1 - Préparation contenant du piment long indien - Google Patents

Préparation contenant du piment long indien Download PDF

Info

Publication number
WO2014010658A1
WO2014010658A1 PCT/JP2013/068934 JP2013068934W WO2014010658A1 WO 2014010658 A1 WO2014010658 A1 WO 2014010658A1 JP 2013068934 W JP2013068934 W JP 2013068934W WO 2014010658 A1 WO2014010658 A1 WO 2014010658A1
Authority
WO
WIPO (PCT)
Prior art keywords
nausea
ethanol
turmeric
gastrointestinal
powder
Prior art date
Application number
PCT/JP2013/068934
Other languages
English (en)
Japanese (ja)
Inventor
祐太 藤枝
Original Assignee
興和株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 興和株式会社 filed Critical 興和株式会社
Priority to JP2014524859A priority Critical patent/JPWO2014010658A1/ja
Publication of WO2014010658A1 publication Critical patent/WO2014010658A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger

Definitions

  • the present invention relates to a drug having an excellent gastrointestinal mucosa protective action and antiemetic action. More specifically, excellent gastrointestinal mucosal protective action against gastrointestinal mucosal damage due to ethanol overdose, stress, overdose, smoking, and nonsteroidal anti-inflammatory drugs, and nausea, nausea or The present invention relates to a drug having an excellent antiemetic action against vomiting.
  • Non-patent Document 1 a gram-negative bacilli
  • Non-patent Document 2 Shay's balance theory
  • antibiotics having anti-Helicobacter pylori activity for example, penicillin, ampicillin, erythromycin, clarithromycin, streptomycin, tetracycline, etc.
  • bismuth preparations are used for the treatment of peptic ulcer caused by Helicobacter pylori. .
  • the mechanism of peptic ulcer caused by an imbalance of attack and defense factors such as hyperacidity is different from that caused by Helicobacter pylori as described above.
  • This includes gastrointestinal mucosa such as overdose of ethanol, stress, dysphagia, smoking, and nonsteroidal anti-inflammatory drugs (aspirin, acetaminophen, ibuprofen, indomethacin, etenzamide, tranexamic acid, loxoprofen, etc.)
  • gastric acid which is an attack factor, becomes relatively excessive due to a reduction in the protective power of the stomach and duodenal mucosa, etc., and damages the gastrointestinal mucosa.
  • gastric acid secretion inhibitors and anti-pepsin agents which are attack factor inhibitors, or mucosal protective agents and tissue repair promoters, which are defense factor enhancers, are used for this treatment.
  • the cause of ulcers in the upper body of the stomach and relapsed refractory ulcers seen in elderly people is often a decrease in protective factors, and it is desired to provide an excellent protective factor enhancer.
  • Patent Document 1 a blend of processed potato, carrot and antacid
  • Patent Document 2 a blend of oxon, turmeric and shochu
  • Hihatsu has the scientific name Piper longum L. Or it is called Pipe retrofractum Vahl and is a plant belonging to the genus Pepperaceae.
  • the dried product of immature fruit spikes has been widely used as a spice with an appetite since ancient times.
  • Hihatsu is also known as a herbal medicine with analgesic / healthy stomach action, blood flow increasing action, antibacterial action, etc., and is used as an antibacterial agent against Helicobacter pylori (Patent Document 3) and as a functional gastroenteropathy treatment agent. It is reported that it is effective for use as a cold improver (Patent Document 5), as a swelling improver (Patent Document 6).
  • baboon is an irritating herbal medicine and enhances gastrointestinal function and promotes gastric acid secretion, so it is not used for the treatment of inflammatory or ulcerative diseases.
  • baboons affect nausea, nausea or vomiting due to ethanol overdose.
  • the present inventors have conducted extensive research, and as a result, found that hihatsu has an excellent gastrointestinal mucosal protective action, and that when combined with turmeric, a synergistic effect can be obtained.
  • the present invention has been completed.
  • the inventor has also found that baboon has an excellent antiemetic action against nausea, nausea or vomiting caused by excessive intake of ethanol, and has completed the present invention. That is, the present invention provides a gastrointestinal mucosal protective agent (hereinafter referred to as the gastrointestinal mucosal protective agent of the present invention) containing hihatsu.
  • the present invention provides an antiemetic containing hihatsu (hereinafter referred to as an antiemetic of the present invention).
  • medical agent which has the outstanding digestive tract mucosa protective effect can be provided.
  • a drug having an excellent gastrointestinal mucosal protective action against gastrointestinal mucosal damage caused by ethanol can be provided. It can be effectively applied to the improvement of various unpleasant symptoms such as stomach pain, nausea and stomach weight after ingestion of ethanol.
  • gastrointestinal mucosal damage caused by stress, heavy drinking and eating, smoking, and nonsteroidal anti-inflammatory drugs can be significantly suppressed.
  • the antiemetic which has the improvement effect excellent with respect to nausea, nausea, or vomiting can be provided. More specifically, it is possible to provide an antiemetic having an excellent improving effect on nausea, nausea or vomiting caused by ethanol intake.
  • the present invention has an excellent ameliorating action particularly on gastrointestinal mucosal damage and vomiting caused by ingestion of ethanol, and therefore can be effectively used as an agent for improving discomfort caused by ingestion of ethanol.
  • the gastrointestinal mucosa protective agent or antiemetic of the present invention contains hihatsu.
  • baboon refers to baboon (Piper longum L. (aka: Indiana pepper) or Piper retrofractum Vahl (aka: Javanaga pepper).
  • Hibatsu is also called Naga Pepper (long pepper), and there is a literature that uses Java Naga Pepper as Hihatu modo in order to distinguish it from Hibatsu in a narrow sense, but in the present invention, Treat both as hihatsu.
  • Hibatsu those made from mature or immature fruit spikes, leaves, petioles, branches, roots, etc. are used.
  • the hihatsu used in the present invention is its fruit head or immature fruit head.
  • These can be used in the form of dried extract powder, which has been appropriately dried, or an extract extracted with water, lower alcohol or a mixed solvent thereof.
  • Specific examples include hihatsu, hihatsu powder, hihatsu extract, hihatsu-style extract, hihatsu dried extract, hihatsu soft extract, and the like.
  • Examples of commercially available products include Hihatsu powder (manufactured by Mikuni Co., Ltd.), Hihatsu extract MF (manufactured by Maruzen Pharmaceutical Co., Ltd.), and the like.
  • Hibatsu used in the present invention is preferably 0.001 to 10% by weight, more preferably 0.01 to 5% by weight in terms of the active ingredient based on the preparation. If this blending amount is less than 0.001% by weight, the effect may be low, and if it exceeds 10% by weight, irritation such as pungency becomes strong, which may be undesirable from the viewpoint of taking feeling.
  • the daily use amount of Hihatsu per adult can be used within the range of 5 g / day, preferably 3 g / day, in terms of the active ingredient, but the single dose is usually 0.001 to The amount is preferably 2 g, preferably in the range of 0.01 to 1 g.
  • turmeric can be used in combination.
  • the turmeric in this case is Ginger family turmeric (Curcuma longa (also known as autumn turmeric) or Curcuma aromatica (also known as spring turmeric)).
  • autumn turmeric and spring turmeric can be used, but it is preferable to use autumn turmeric.
  • Turmeric used in the present invention is preferably rhizome as it is or boiled except for pericarp, and further extracted with powdered turmeric powder, water, lower alcohol or a mixed solvent thereof. What was made into the extracted extract is still more preferable.
  • Specific examples include turmeric, turmeric powder, turmeric extract, turmeric extract, turmeric dry extract, turmeric soft extract, and fermented turmeric, and turmeric powder or turmeric extract is preferred.
  • examples of commercially available products include turmeric powder (manufactured by Nippon Powder Chemical Co., Ltd.), turmeric extract (manufactured by Nippon Powder Chemical Co., Ltd., Maruzen Pharmaceutical Co., Ltd.), and the like.
  • turmeric When turmeric is used together in the present invention, it is preferably 0.1 to 60% by weight, more preferably 0.5 to 30% by weight in terms of the active ingredient based on the preparation. If the blending amount is less than 0.1% by weight, the effect may be low. If the blending amount exceeds 60% by weight, the astringency becomes strong, which is not preferable in terms of taking feeling.
  • the amount of turmeric used per day for an adult can be used in the range of 10 g / day, preferably 6 g / day, in terms of the active ingredient, but the single dose is usually 0.01 to 1 in terms of the active ingredient. The amount is preferably 6 g, preferably in the range of 0.1 to 2 g.
  • the weight ratio of baboon to turmeric is preferably 1: 0.01 to 1: 120, and 1: 0.1 to 1:60 in terms of the active ingredient. Is more preferable, and 1: 1 to 1:10 is particularly preferable.
  • the gastrointestinal mucosal protective agent or antiemetic containing the rabbit of the present invention can be used as a remedy for discomfort caused by ingestion of ethanol, either after ingestion of ethanol (especially the next day), before ingestion of ethanol or even during ingestion of ethanol.
  • the gastrointestinal mucosa protective agent or antiemetic of the present invention is preferably taken orally.
  • the gastrointestinal mucosa protective agent of the present invention can be used for the treatment or prevention of gastrointestinal mucosal disorder or peptic ulcer, and in particular, digestive tract mucosal damage after ethanol intake, digestion caused by excessive intake of ethanol.
  • Excellent therapeutic or preventive effects are observed for gastrointestinal ulcers or gastrointestinal mucosal disorders and peptic ulcers caused by stress, heavy drinking and eating, smoking, and nonsteroidal anti-inflammatory drugs.
  • it can be effectively applied to improve unpleasant symptoms such as gastric pain, nausea, and stomach weight after ingestion of ethanol or after stress, heavy drinking and eating, smoking, and taking non-steroidal anti-inflammatory drugs. .
  • the gastrointestinal mucosa includes gastric mucosa or duodenal mucosa.
  • the antiemetic of the present invention is used for suppressing or preventing nausea, nausea or vomiting, and can be applied as an antiemetic for nausea, nausea or vomiting associated with the following causes or diseases.
  • the causes or diseases of nausea, nausea or vomiting include ethanol overdose, stress, motion sickness, food poisoning, cold body, pregnancy (morning), accidental ingestion of foreign bodies, side effects due to drugs, acute gastritis, stomach Duodenal ulcer, appendicitis, bowel obstruction, acute peritonitis, pancreatitis, migraine, Meniere disease, cerebral hemorrhage, brain tumor, subarachnoid hemorrhage, acute cholecystitis, acute hepatitis, alcoholic hepatitis, cholelithiasis, gastric polyp, fatty liver, pneumonia, glaucoma, Or chronic subdural hematoma etc. are mentioned.
  • the gastrointestinal mucosa protective agent or antiemetic of the present invention can be preferably used as a discomfort symptom improving agent by ingesting ethanol.
  • the unpleasant symptom caused by ingestion of ethanol means stomach pain, nausea, stomach weight, nausea, nausea or vomiting caused by ingestion of ethanol.
  • alcohol is synonymous with ethanol.
  • the gastrointestinal mucosa protective agent or antiemetic of the present invention may be used in combination with other gastrointestinal mucosa protective agent or antiemetic.
  • the gastrointestinal mucosa protective agent or antiemetic of the present invention may further contain the following active ingredients and additives as necessary. Active ingredients include other gastrointestinal mucosal protective agents, other antiemetics, blood alcohol level lowering accelerators, antacids, stomachic agents, liver function improving agents, digestive agents, intestinal regulating agents, antipruritics, analgesic antispasmodics, gastric mucosa Examples include restoration agents, vitamins, and antifoaming agents.
  • Examples of the blood alcohol concentration lowering promoter include turmeric, amino acids (alanine, glutamine), rainbow trout, cordyceps, citrus molasses (derived from Wenzhou oranges), ⁇ -lactalbumin, lactulose, maltitol, lactitol, glycerol, oleanolic acid, Presenegenin, Hederagenin, Protoesigenin, Caffeine, Chixetsunin, Kyokyo, Carnitine chloride, Glycylglycine, Pepino, Kuzune, Mung bean, Red bean, Santo, Malt, Kawamata, Kashiwa, Akiko, Sandhi, Light load, Fructose, Ginseng , Komi-sou hot water or Kazuwa-to fermented lactic acid bacteria, guava, dry activated yeast, fructose, ascorbic acid, aroma substance, citric acid, kinin and the like.
  • amino acids alanine, glut
  • antacids include synthetic hydrotalcite, magnesium oxide, magnesium silicate, magnesium aluminate silicate, aluminum silicate, magnesium aluminate metasilicate, magnesium hydroxide, aluminum hydroxide, magnesium alumina hydroxide, dihydroxy Aluminum aminoacetate, sodium hydrogencarbonate, calcium carbonate, magnesium carbonate, calcium hydrogenphosphate, aminoacetic acid, funnel extract and the like can be mentioned.
  • stomachic agent for example, anise, aloe, fennel, yak, turmeric, life-grass, ogon, oak, auren, processed garlic, garlic, cuckoo, columnar root, psoriasis, rice husk, pheasant, keihi, gentian, Koujin, Kokuboku, Goshuyu, Pepper, Colombo, Conzurango, Sanshishi, Salamander, Yamana, Shisoshi, Shukusha, Shokyo, Shozu, Green peel, Ishizone, Centaurium grass, Assembly, Sowjutsu, Soyo, Daisuke, Daio, Takusha, Chiku Setu carrot, clove, chorei, chimpi, capsicum, spruce, animal gall (including yutan), oyster mushroom, nutmeg, carrot, mint (including Atlantic mint), peanut, broomfish, hops, honey extract, rape leaves (Saisai), Mokk
  • liver function improving agent examples include, for example, liver hydrolyzate, Maria thistle, Tabana carrot, turmeric, indigo, dandelion, western dandelion, burdock, garlic, chrysanthemum, yarrow, gardenia, sesame, asparagus, onion, chicory, Medicinal salvia, Korean thistle (artichoke), wolfberry, legumes / iridaceae / rose family plants (eg, soybeans and kudzu, asparagus linearias belonging to legumes), Japanese quail, elba de pasarinho, cetesangria, red buds, Black tea, Saiko, Peach seed, Peony skin, Safflower, Sanjyo, Gadju, ⁇ -lipoic acid, Flavonols, Flavones, Flavans, Flavanols, Catechins, Isoflavones, Lignanoic acid, Curcuminoids, Gluterin, Prolamin, Glutathione
  • Examples of the digestive agent include starch digestive enzyme, protein digestive enzyme, fat digestive enzyme, fibrin digestive enzyme, ursodesoxycholic acid, oxycoranoates, cholic acid, bile powder, bile extract (powder), dehydrocol Acid, animal gall (including yutan) and the like.
  • intestinal adjusting agent examples include live intestinal fungi components, natto kinase, akame koji, asenyaku, aloe, ubai, ketsumeishi, genokosho, plantago obata and the like.
  • Antidiarrheal agents include, for example, acrinol, berberine chloride, guaiacol, creosote, phenyl salicylate, guaiacol carbonate, berberine tannate, bismuth hyposalicylate, bismuth nitrate, bismuth carbonate, bismuth gallate, tannic acid, albumin tannate , Methylene thymol tannin, kaolin, pectin, medicinal charcoal, calcium lactate, Acacia yam, buckwheat, duckweed, auren, kudin, ganodermone, pentaploid, hawthorn, yellowtail, ivy.
  • analgesic and antispasmodic agents include oxyphencyclimine hydrochloride, dicyclomine hydrochloride, methixene hydrochloride, scopolamine hydrobromide, methyl atropine bromide, methyl anisotropine bromide, methyl scopolamine bromide, butyl scopolamine bromide, methyl bromide- l-hyostiamine, methylbenactidium bromide, belladonna extract, belladonna total alkaloid, iodopropamide, diphenylpiperidinomethyldioxolane iodide, funnel extract, funnel root total alkaloid citrate, papaverine hydrochloride, engosac, licorice, Examples include kokuboku and peonies.
  • gastric mucosa repairing agent examples include sodium azulenesulfonate, aldioxa, glycyrrhizic acid and salts thereof, and licorice extract, L-glutamine, copper chlorophyllin potassium, copper chlorophyllin sodium, histidine hydrochloride, porcine gastric wall pepsin degradation product, porcine gastric wall acid Hydrolysates, methylmethionine sulfonium chloride, red buds, engosac, licorice, sucralfate, rebamipide, marzulene, polaprezinc, sodium alginate, gefarnate, teprenone, troxipide, benexate betadex, prunotol, irsogladine maleate, sofalcone, etc. It is done.
  • vitamins include nicotinic acid amide, calcium pantothenate, biotin, vitamin B 1 or a derivative or salt thereof, vitamin B 2 or a derivative or salt thereof, vitamin B 6 or a derivative or salt thereof, vitamin C or Examples thereof include vitamin E or a derivative thereof or a salt thereof.
  • antifoaming agent examples include dimethylpolysiloxane.
  • antiemetics include, for example, granisetron, domperidone, sulpiride, ondansetron, azasetron, dimenhydrinate, metoclopramide, chlorpromazine, diphenidol hydrochloride, diphenhydramine, diphenhydramine hydrochloride, meclizine, promethazine, chlorpheniramine, chlorpheniline maleate Lamin, amphetamine, atropine, bromvalerylurea, allylisopropylacetylurea, caffeine, theophylline, mint oil, menthol, vitamin B6 and the like can be mentioned.
  • Additives include physiologically excipients, binders, disintegrants, lubricants, stabilizers, thickeners, solubilizers, preservatives, pH adjusters, colorants, sweeteners, etc. There are various acceptable types.
  • excipient examples include lactose, starches, crystalline cellulose, sucrose, mannitol, light anhydrous silicic acid and the like.
  • binder examples include hydroxypropylmethylcellulose, hydroxypropylcellulose, gelatin, pregelatinized starch, polyvinylpyrrolidone, polyvinyl alcohol, pullulan and the like.
  • disintegrant examples include carmellose, carmellose calcium, croscarmellose sodium, crospovidone, corn starch, and low-substituted hydroxypropylcellulose.
  • Examples of the lubricant include magnesium stearate and talc.
  • the stabilizer examples include ascorbic acid, edetic acid, and salts thereof.
  • thickener examples include carmellose sodium, agar, gelatin, polyvinyl alcohol, polyvinyl pyrrolidone and the like.
  • solubilizer examples include nonionic surfactants such as hydrogenated oil, glyceryl monostearate, polyoxyethylene hydrogenated castor oil, and sucrose fatty acid ester, and lecithin.
  • preservative examples include benzoic acid, sodium benzoate, methyl paraoxybenzoate, ethyl paraoxybenzoate, propyl paraoxybenzoate, isopropyl paraoxybenzoate, butyl paraoxybenzoate, isobutyl paraoxybenzoate and the like.
  • pH adjuster examples include citric acid, malic acid, lactic acid, tartaric acid, acetic acid, hydrochloric acid, phosphoric acid, and salts thereof, sodium hydroxide, potassium hydroxide, magnesium hydroxide, calcium hydroxide, and the like.
  • Examples of the colorant include titanium oxide, tar pigment, yellow No. 4, yellow No. 5, ferric oxide, yellow ferric oxide, red No. 3 and the like.
  • sweetening agent examples include sucrose, liquid sugar, fructose, fructose glucose liquid sugar, reduced maltose water candy, honey, caramel, sorbitol, maltitol, xylitol, erythritol, sucralose, stevia, glycyrrhizic acid or a salt thereof, aspartame, acesulfame Potassium etc. are mentioned.
  • the gastrointestinal mucosa protective agent or antiemetic of the present invention can be taken alone, or it can be contained in a pharmaceutical composition together with other active ingredients and additives, or in the form of a food additive or food supplement. It can also be used as a health food and drink by containing it in various foods and drinks. Moreover, according to the objective of this invention, it can manufacture in dosage forms, such as a liquid agent, a powder, a granule, a tablet, a chewable tablet, a film-coated tablet, a sugar-coated tablet, a soft capsule, a hard capsule, and a jelly agent by a well-known and usual technique.
  • the gastrointestinal mucosal protective agent of the present invention pharmaceuticals or foods and drinks containing the same are used to improve gastrointestinal mucosal damage caused by alcohol consumption, stress, overdrinking, smoking, and taking non-steroidal anti-inflammatory drugs, etc.
  • An indication that it is used for prevention may be attached. For example, indications such as “to prevent or alleviate stomach pain, nausea, stomach weight, etc.”, “drink before drinking alcohol to prevent nausea”, “energetic next day after drinking”, etc.
  • such a display can be attached to the container packaging means by a known method, whereby the gastrointestinal mucosa protective agent of the present invention, the pharmaceutical or food or drink containing the same, alcohol intake, stress, overdrinking, Since it is clearly stated that it is used for the improvement and / or prevention of gastrointestinal mucosal damage caused by smoking and taking non-steroidal anti-inflammatory drugs, etc. Becomes clear.
  • the antiemetic of the present invention medicines or foods and drinks containing the same may be labeled for use in the improvement and / or prevention of nausea, nausea or vomiting caused by alcohol consumption.
  • indications such as “to prevent or relieve nausea, nausea and vomiting”, “prevent nausea by drinking before drinking”, “energetic next day after drinking”, etc.
  • a display can be attached to the container and packaging means by a publicly known method, whereby the antiemetic of the present invention, a medicine containing the same, or a food or drink can improve various symptoms caused by alcohol intake and / or Or, since it is clearly indicated that it is used for prevention, the distinction from normal agents, pharmaceuticals or foods and drinks becomes clear.
  • Test Example 1 Effect on gastric mucosal damage model A Wistar male rat (8 weeks old) fasted overnight with a suspension of the test substance in physiological saline (but only physiological saline as a control) Oral administration (5 mL / kg) was performed, and 30 minutes later, 99.5 vol% ethanol was orally administered at 1 mL / animal. One hour after ethanol administration, the stomach was removed, fixed with 1% by volume formalin, the stomach was cut open, and the length of damage (damage factor) occurring in the gastric mucosa was measured.
  • test substances were control (saline), turmeric powder (autumn turmeric) 600 mg / kg, chickweed powder (Jawa Naga pepper) 150 mg / kg, and turmeric powder (autumn turmeric) 600 mg / kg + hihatsu powder (Jawa Naga pepper) )
  • test substances were control (saline), turmeric powder (autumn turmeric) 600 mg / kg, chickweed powder (Jawa Naga pepper) 150 mg / kg, and turmeric powder (autumn turmeric) 600 mg / kg + hihatsu powder (Jawa Naga pepper) )
  • Four groups of 150 mg / kg combined. The result of the gastric mucosa damage inhibitory effect when each test substance is administered is shown in FIG.
  • turmeric powder 600 mg / kg suppressed the occurrence of ulcers
  • hihatsu powder 150 mg / kg exhibited an antiulcer action superior to that of the control.
  • a further superior anti-ulcer action was confirmed as compared with chickpea powder 150 mg / kg alone.
  • the average ulcer index of each group was 0.50 in the turmeric powder group and 0.26 in the chickweed powder group when the control was 1, and the product (0.13) was 0.
  • turmeric The anti-ulcer action of baboon was greatly promoted by combined use with turmeric (Burgi method: Keijiro Takagi et al .: Pharmacology, 1987, Nanzan-do). From the above, it was shown that both turmeric and baboon have excellent gastric mucosal protective action against gastric mucosal damage caused by ethanol intake. It was also shown that when turmeric and hihatsu were administered in combination, both components acted synergistically to provide an excellent gastric mucosa protective effect. In this example, in order to create a gastric mucosal damage model, ethanol was used to induce ulcers, but not limited to ethanol, such as stress, heavy drinking and eating, smoking, and after taking nonsteroidal anti-inflammatory drugs, etc. It has the same effect on ulcers caused by factors.
  • Example 1 Preparation of a Japanese pine plant formulation To 10 mL of purified water, 50 mg of pine powder, 45 mg of oxoamidin powder, 135 mg of carrot dry extract, 200 mg of turmeric powder, 0.3 mL of lauren extract, 100 mg of dried gentian powder, 82 mg of licorice extract powder were added. (Formulation liquid 1). Separately, 1.5 g of purified white sugar and 0.09 g of polyvinylpyrrolidone were added to 10 mL of purified water, and this was heated and dissolved. This liquid was mixed with the preparation liquid 1 prepared above, and sodium citrate was added to adjust the pH to 5. An appropriate amount of purified water was added thereto to make a total volume of 50 mL to obtain an internal solution.
  • Formulation liquid 1 Separately, 1.5 g of purified white sugar and 0.09 g of polyvinylpyrrolidone were added to 10 mL of purified water, and this was heated and dissolved. This liquid was mixed with the preparation liquid 1
  • Comparative Example 1 Preparation of a non-hihatsu formulation Water was used as a control.
  • Comparative Example 2 Preparation of non-hihatsu formulation Solmac Plus (Takuma Pharmaceutical Co., Ltd.) was used.
  • Solmac Plus includes turmeric extract 0.3 mL, licorice extract 135 mg, carrot extract 0.5 mL, aurin tincture 0.826 mL, clove tincture 0.126 mL, gentian tincture 0.376 mL, and sojutsu extract 1.2 mL, cinnamon tincture 0.25 mL, and carnitine chloride 120 mg are blended.
  • Test Example 2 Evaluation of antiemetic effect Obtained in Example 1, Comparative Example 1 or Comparative Example 2 using an 11-month-old male Suncus (Suncus murinus) that was given food (CIEA-312) and water freely.
  • n 6 for each group.
  • 40% ethanol was further orally administered to 5 mg / kg, and the vomiting reaction to the test sunx was observed for 60 minutes after ethanol administration. In this experiment, when there was vomiting of the stomach contents, it was considered that there was a vomiting reaction.
  • Example 1 containing hihatsu had fewer vomiting times than Comparative Examples 1 and 2.
  • the time to show vomiting reaction was also reduced. Based on these results, it was shown that the inclusion of baboon has the effect of suppressing the vomiting reaction itself, not the delay of the vomiting reaction, and can contribute to quick recovery from unpleasant conditions such as nausea, nausea or vomiting. .
  • the following production examples 1 to 4 show production examples of the gastrointestinal mucosa protective agent or antiemetic of the present invention.
  • 450 parts by weight of dry aluminum hydroxide gel, 325 parts by weight of magnesium hydroxide, 450 parts by weight of synthetic hydrotalcite, 75 parts by weight of licorice extract powder, 200 parts by weight of fennel powder, 200 parts by weight of turmeric powder (autumn turmeric), carrot A kneaded product was prepared by adding 800 parts by mass of 70% ethanol to a mixed powder comprising 20 parts by mass of a dry extract, 70 parts by mass of polyvinyl alcohol, 30 parts by mass of carmellose calcium, 40 parts by mass of crystalline cellulose, and 1545 parts by mass of xylitol.
  • the kneaded product was extruded and granulated ( ⁇ 0.8 mm), dried, sized and classified to obtain granules (hereinafter referred to as B granules). Further, 6 parts by mass of L-menthol was adsorbed on 24 parts by mass of magnesium aluminate metasilicate to obtain a fragrance powder (hereinafter referred to as C fragrance powder). 165 parts by mass of A granule, 3405 parts by mass of B granule, and 30 parts by mass of C fragrance powder were mixed by a mixer, and further packed by a packaging machine to obtain a granule having a single dose of 1.2 g.
  • 450 parts by weight of dry aluminum hydroxide gel, 325 parts by weight of magnesium hydroxide, 450 parts by weight of synthetic hydrotalcite, 75 parts by weight of licorice extract powder, 200 parts by weight of fennel powder, 200 parts by weight of turmeric powder (autumn turmeric), show Add 700 parts by mass of 90% ethanol to a mixed powder consisting of 100 parts by mass of carp powder, 20 parts by mass of dried carrot extract, 90 parts by mass of hydroxypropyl cellulose, 30 parts by mass of carmellose calcium, 30 parts by mass of crystalline cellulose, and 1445 parts by mass of erythritol. A kneaded product was made.
  • the kneaded product was dried and sized to obtain granules (hereinafter referred to as B granules). Further, 4 parts by mass of L-menthol was adsorbed on 16 parts by mass of magnesium aluminate metasilicate to obtain a fragrance powder (hereinafter referred to as C fragrance powder). 165 parts by mass of A granules, 3415 parts by mass of B granules, and 20 parts by mass of C fragrance powder were mixed with a mixer, and further packaged with a packaging machine to obtain a granule having a single dose of 1.2 g.
  • the gastrointestinal protective agent of the present invention contains baboon, gastrointestinal mucosal damage or peptic ulcer caused by excessive intake of ethanol, stress, violent eating and eating, smoking, and taking non-steroidal anti-inflammatory drugs, etc. Has an excellent preventive and / or therapeutic effect. Furthermore, a synergistic effect is acquired by using turmeric together. Moreover, the antiemetic of this invention has the antiemetic effect excellent with respect to nausea, nausea, or vomiting by containing a hihatsu. In particular, it has an excellent antiemetic action against nausea, nausea or vomiting caused by excessive intake of alcohol, and these symptoms can be quickly improved.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Botany (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne un agent médicinal ayant un excellent effet de prévention/traitement de l'endommagement des muqueuses du tractus gastro-intestinal ou de l'ulcère gastroduodénal induit par l'ingestion excessive d'éthanol, le stress, la consommation abusive d'aliment/d'alcool, le tabac, la prise d'un agent anti-inflammatoire non stéroïdien et analogues et possédant également un excellent effet antiémétique contre une sensation de nausée ou de vomissement induite par la consommation abusive d'alcool. Un agent de protection des muqueuses du tractus gastro-intestinal ou un agent antiémétique est préparé par l'addition de piment long indien à une préparation. Lors de l'ajout de curcuma à l'agent de protection des muqueuses du tractus gastro-intestinal, un effet synergique peut être obtenu.
PCT/JP2013/068934 2012-07-11 2013-07-11 Préparation contenant du piment long indien WO2014010658A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2014524859A JPWO2014010658A1 (ja) 2012-07-11 2013-07-11 ヒハツ配合製剤

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2012155659 2012-07-11
JP2012155663 2012-07-11
JP2012-155659 2012-07-11
JP2012-155663 2012-07-11

Publications (1)

Publication Number Publication Date
WO2014010658A1 true WO2014010658A1 (fr) 2014-01-16

Family

ID=49916099

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2013/068934 WO2014010658A1 (fr) 2012-07-11 2013-07-11 Préparation contenant du piment long indien

Country Status (2)

Country Link
JP (1) JPWO2014010658A1 (fr)
WO (1) WO2014010658A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015077124A (ja) * 2013-09-13 2015-04-23 大正製薬株式会社 飲料
JP2017537944A (ja) * 2014-12-12 2017-12-21 アリ ヘルスケア ピーブイティー リミテッドＡｒｉ Ｈｅａｌｔｈｃａｒｅ Ｐｖｔ． Ｌｔｄ． 口内リフレッシャー
CN109453362A (zh) * 2019-01-16 2019-03-12 汤臣倍健股份有限公司 一种保护胃黏膜及抗幽门螺旋杆菌的组合物及其应用
JP2019202995A (ja) * 2018-05-17 2019-11-28 大正製薬株式会社 経口組成物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58162520A (ja) * 1982-03-23 1983-09-27 Res Inst For Prod Dev 抗潰瘍剤
JP2005526791A (ja) * 2002-03-25 2005-09-08 カウンシル・オブ・サイエンティフィック・アンド・インダストリアル・リサーチ 胃潰瘍を治療するための組成物およびそれを製造するための方法
JP2006104109A (ja) * 2004-10-04 2006-04-20 Maruzen Pharmaceut Co Ltd むくみ感改善剤及びむくみ感改善用飲食物
JP2011184381A (ja) * 2010-03-10 2011-09-22 Maruzen Pharmaceut Co Ltd アデノシン三リン酸産生促進剤及びアデノシン三リン酸産生量低下に起因する疾患の予防・治療剤

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003226650A (ja) * 2001-11-30 2003-08-12 Daito Kk 医薬用組成物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58162520A (ja) * 1982-03-23 1983-09-27 Res Inst For Prod Dev 抗潰瘍剤
JP2005526791A (ja) * 2002-03-25 2005-09-08 カウンシル・オブ・サイエンティフィック・アンド・インダストリアル・リサーチ 胃潰瘍を治療するための組成物およびそれを製造するための方法
JP2006104109A (ja) * 2004-10-04 2006-04-20 Maruzen Pharmaceut Co Ltd むくみ感改善剤及びむくみ感改善用飲食物
JP2011184381A (ja) * 2010-03-10 2011-09-22 Maruzen Pharmaceut Co Ltd アデノシン三リン酸産生促進剤及びアデノシン三リン酸産生量低下に起因する疾患の予防・治療剤

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Protective action of piperine against experimental gastric ulcer.", ACTA PHARMACOLOGICA SINICA, vol. 21, no. 4, 2000, pages 357 - 359 *
HISASHI MATSUDA ET AL.: "Gastroprotective Constituents from Several Spices and Their Structural Requirements for the Activity and Mode of Action : Tasmannia lanceolata, Alpinia galanga, Piper chaba, and Boesenbergia rotunda", SYMPOSIUM ON THE CHEMISTRY OF NATURAL PRODUCTS, SYMPOSIUM PAPERS, vol. 46, 1 September 2004 (2004-09-01), pages 611 - 615 *
KATSUYUKI SASAHARA ET AL.: "Examination of changes in energy metabolism in gastric mucosa and quantity of mucus influenced by administration of adenosine triphosphate in patients of chronic gastritis", RINSHO TO KENKYU, vol. 76, no. 10, 1999, pages 185 - 188 *
SHOGAKUKAN INC.,, CHUYAKU DAIJITEN, 1ST EDITION, 10 December 1985 (1985-12-10), pages 2227 - 2228 *
T MORIKAWA ET AL.: "New amides and gastroprotective constituents from the fruit of Piper chaba.", PLANTA MED., vol. 70, no. 2, 2004, pages 152 - 159 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015077124A (ja) * 2013-09-13 2015-04-23 大正製薬株式会社 飲料
JP2020150953A (ja) * 2013-09-13 2020-09-24 大正製薬株式会社 飲料
JP2017537944A (ja) * 2014-12-12 2017-12-21 アリ ヘルスケア ピーブイティー リミテッドＡｒｉ Ｈｅａｌｔｈｃａｒｅ Ｐｖｔ． Ｌｔｄ． 口内リフレッシャー
JP2019202995A (ja) * 2018-05-17 2019-11-28 大正製薬株式会社 経口組成物
JP7283216B2 (ja) 2018-05-17 2023-05-30 大正製薬株式会社 経口組成物
CN109453362A (zh) * 2019-01-16 2019-03-12 汤臣倍健股份有限公司 一种保护胃黏膜及抗幽门螺旋杆菌的组合物及其应用

Also Published As

Publication number Publication date
JPWO2014010658A1 (ja) 2016-06-23

Similar Documents

Publication Publication Date Title
JPWO2002096406A1 (ja) 医薬組成物
JP6345243B2 (ja) 円武扇発酵物含有食品または飲料組成物
WO2014010656A1 (fr) Agent d'accélération de la baisse de concentration d'alcool supérieur dans le sang
JP2014015430A (ja) 深部体温上昇剤
WO2014010658A1 (fr) Préparation contenant du piment long indien
JP5679721B2 (ja) 漢方エキスを含有する医薬組成物
JP2008056567A (ja) 胃腸疾患の治療又は予防のための医薬
US8158171B2 (en) Methods of lowering blood cholesterol via oral fenugreek seed extract compositions
KR101910013B1 (ko) 한약재 추출물（ｓｏｃｇ）을 함유하는 통증의 개선, 예방 또는 치료용 조성물
JP4667244B2 (ja) 医薬組成物
KR101528557B1 (ko) 천년초 발효물 함유 의약 조성물
WO2010087150A1 (fr) Inhibiteur de la sécrétion d'acide gastrique et inhibiteur du canal potassique
JP5823131B2 (ja) 防風通聖散含有組成物
JP4950551B2 (ja) 消化管粘膜保護剤
KR20200140103A (ko) 틱장애, 뚜렛증후군 또는 강박장애의 예방 또는 치료용 조성물
JP2009057336A (ja) 羅漢果エキスを含有する創傷治癒促進組成物と適用方法
JP7263151B2 (ja) 経口組成物
JP2005162713A (ja) 内服用組成物
JP2007145731A (ja) 止瀉効果を有する内服用製剤
WO2017084631A9 (fr) Composition pharmaceutique et méthode destinées à prévenir ou traiter le foie gras, à améliorer les pathologies provoquées par un foie gras, le diabète sucré ou d'autres maladies associées
JP6114133B2 (ja) クコシエキス含有内服液剤、可溶化剤および可溶化方法
JP7452777B2 (ja) 生活の質改善又は維持用組成物
JP7369931B2 (ja) 風邪症状緩和用飲食品組成物
JP2003342186A (ja) 鼻炎用内服液剤組成物
JP2004091420A (ja) 内服用医薬組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13816312

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2014524859

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2015/00276

Country of ref document: TR

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13816312

Country of ref document: EP

Kind code of ref document: A1